Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M. Kuriwaki I, et al. Among authors: iwai y. Bioorg Med Chem. 2020 May 15;28(10):115453. doi: 10.1016/j.bmc.2020.115453. Epub 2020 Mar 28. Bioorg Med Chem. 2020. PMID: 32278710
Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.
Iikubo K, Kurosawa K, Matsuya T, Kondoh Y, Kamikawa A, Moritomo A, Iwai Y, Tomiyama H, Shimada I. Iikubo K, et al. Among authors: iwai y. Bioorg Med Chem. 2019 Apr 15;27(8):1683-1692. doi: 10.1016/j.bmc.2019.03.018. Epub 2019 Mar 7. Bioorg Med Chem. 2019. PMID: 30878193
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Kondoh Y, Terasaka T, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Nakazawa T, Hirano M. Kuriwaki I, et al. Among authors: iwai y. Bioorg Med Chem. 2021 Mar 1;33:116019. doi: 10.1016/j.bmc.2021.116019. Epub 2021 Jan 16. Bioorg Med Chem. 2021. PMID: 33486159
Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.
Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Terasaka T, Iwai Y, Noda A, Tomiyama H, Kikuchi A, Hirano M. Kuriwaki I, et al. Among authors: iwai y. Bioorg Med Chem. 2022 Apr 1;59:116657. doi: 10.1016/j.bmc.2022.116657. Epub 2022 Feb 11. Bioorg Med Chem. 2022. PMID: 35219181
Effective preparation of cycloheptimidazol-4-one compounds.
Sonegawa M, Iwai Y, Tomiyama H, Tomiyama T. Sonegawa M, et al. Among authors: iwai y. Chem Pharm Bull (Tokyo). 2006 May;54(5):703-5. doi: 10.1248/cpb.54.703. Chem Pharm Bull (Tokyo). 2006. PMID: 16651772 Free article.
Inter-fractional error and intra-fractional motion of prostate and dosimetry comparisons of patient position registrations with versus without fiducial markers during treatment with carbon-ion radiotherapy.
Iwai Y, Mori S, Ishikawa H, Kanematsu N, Matsumoto S, Nakaji T, Okonogi N, Kobayashi K, Wakatsuki M, Uno T, Yamada S. Iwai Y, et al. Radiol Phys Technol. 2024 May 1. doi: 10.1007/s12194-024-00808-8. Online ahead of print. Radiol Phys Technol. 2024. PMID: 38691309
[7. Calculation Algorithm for Electron Beam Therapy].
Iwai Y. Iwai Y. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2024;80(4):421-426. doi: 10.6009/jjrt.2024-2345. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2024. PMID: 38644224 Free article. Japanese. No abstract available.
616 results